A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Remibrutinib (Primary)
- Indications Chronic urticaria
- Focus Registrational; Therapeutic Use
- Acronyms REMIX-2
- Sponsors Novartis Pharmaceuticals
- 31 May 2024 According to a Novartis media release, exciting long-term data from this study will be submitted to global health authorities later this year.
- 31 May 2024 According to a Novartis media release, data from this study are being presented at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain, May 31-June 3.
- 31 May 2024 Results presented in a Novartis Media Release.